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To compare the relative effectiveness of angiotensin-
converting enzyme inhibitors (ACEIs) and angiotensin
receptor blockers (ARBs) in reducing cardiovascular mortality
in chronic hemodialysis patients, we conducted an
observational analysis of all patients initiated on ACEI or ARB
therapy undergoing chronic hemodialysis at a large dialysis
provider. Survival curves with mortality hazard ratios (HRs)
were generated using the Kaplan–Meier method and Cox
regression. Outcomes were compared using inverse
probability of treatment weighting and propensity score
matching. Over 6 years, 22,800 patients were newly initiated
on an ACEI and 5828 on an ARB after at least 60 days of
chronic hemodialysis. After adjustment for baseline
cardiovascular risk factors, there was no significant difference
in the risk of cardiovascular, all-cause, or cerebrovascular
mortality in patients initiated on an ARB compared with an
ACEI (HR of 0.96). A third of 28,628 patients, newly started
on an ACEI or ARB, went on to another antihypertensive
medication in succession. After adjustment for risk factors,
701 patients initiated on combined ACEI and ARB therapy
(HR of 1.45) or 6866 patients on ACEI and non-ARB
antihypertensive agent (HR of 1.27) were at increased risk of
cardiovascular death compared with 1758 patients initiated
on an ARB and non-ACEI antihypertensive therapy. Thus,
an ARB, in combination with another antihypertensive
medication (but not an ACEI), may have a beneficial effect
on cardiovascular mortality. As observational studies may be
confounded by indication, even when adjusted, randomized
clinical trials are needed to confirm these findings.
Kidney International (2011) 80, 978–985; doi:10.1038/ki.2011.228;
published online 20 July 2011
KEYWORDS: ACE inhibitors; angiotensin; chronic hemodialysis; chronic
inflammation; oxidative stress
More than 20,000 patients on maintenance dialysis are
expected to die from cardiovascular disease this year. The risk
of cardiovascular events in end-stage renal disease (ESRD) is
3.4-fold higher than that of the general population.1
Although risk factors for coronary artery disease (CAD),
such as diabetes and hypertension, are prevalent among
ESRD patients, conventional risk factors alone fail to explain
all of the excess cardiovascular mortality in epidemiological
studies.2 Furthermore, modification of these risk factors has
not been shown so far to be effective in reducing
cardiovascular risk in ESRD.3–5 Consequently, there is a
need to evaluate alternate therapies that could potentially
moderate cardiovascular disease progression in the dialysis
population.
Both angiotensin-converting enzyme inhibitors (ACEIs)
and angiotensin type 1 (AT1) receptor blockers (ARBs)
reduce cardiovascular events within the general popula-
tion.6–14 The comparative effectiveness of ACEIs and ARBs
in reducing cardiovascular mortality in patients at risk for
cardiovascular disease is currently controversial,10 as is the
efficacy of combined ACEI and ARB therapy.10,14
Even less is known about the relative efficacy and safety
of ACEIs and ARBs in ESRD, as only a few studies have
examined the individual efficacy of ACEIs or ARBs versus
no treatment.15–18 There have been no comparative effective-
ness studies between ACEIs and ARBs in the ESRD patient
population to date, despite the widespread prescription of
these drugs among dialysis patients.19,20
To compare the effects of ACEIs and ARBs on cardiovas-
cular mortality in chronic hemodialysis (CHD) patients,
we conducted an observational analysis of outcomes in all
patients undergoing CHD at a large dialysis provider, who
were initiated on therapy with an ACEI, ARB, or both
an ACEI and an ARB.
RESULTS
We surveyed 291,607 ESRD patients who received chronic
dialysis at Fresenius Medical Care America over a 6-year
period. Among this population, 22,800 CHD patients were
newly initiated on an ACEI and 5828 patients on an ARB
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after at least 60 days of CHD (9.8% of the population).
Patients were followed up for an average of 1.26 years (ACEI
users: 1.27 years; ARB users: 1.24 years).
When compared with ARB users, the ACEI group was
more likely to be male, black, and diabetic, and more likely to
have documented CAD, congestive heart failure, or history of
stroke (Table 1). Baseline blood pressures were 2mmHg
systolic and 1mmHg diastolic lower in the ACEI group when
compared with the ARB group (Po0.0001); however, blood
pressure responses to ACEI and ARB initiation were not
different. These differences were successfully balanced after
propensity score adjustment (see propensity score P-value in
Table 1). The number of events for the three mortality
outcomes (cardiovascular, all-cause, and cerebrovascular
death) and for adverse events (hyperkalemia, orthostatic
hypotension, risk of fall) is listed in Table 2.
In unadjusted models, initiation of an ARB (versus ACEI)
was associated with a significantly decreased risk of
cardiovascular death (hazard ratio (HR)¼ 0.87; 95% con-
fidence interval 0.80–0.95) and death due to any cause
(HR¼ 0.90; 95% confidence interval 0.85–0.95), but not with
cerebrovascular mortality (Figure 1a and Table 2). After
adjustment for baseline covariates and weighting for the
inverse probability of treatment, there was no significant
difference in the risk of cardiovascular, all-cause, or
cerebrovascular mortality in patients initiated on an ARB
versus ACEI (Figure 1b). There were also no statistical
interaction effects by patient characteristic on mortality
(Supplementary Figure S1 online). In a matched propensity
score cohort, 4880 patients treated with ACEI were compared
with 4880 patients treated with ARB. Baseline characteristics
were similar in the matched cohort (Supplementary
Table S1 online), and HRs were not different from those
obtained after covariate adjustment and weighted for the
inverse probability of treatment (Table 2).
Combination (ACEI+ARB) versus (ACEI+other antihyperten-
sive) versus (ARB+other antihypertensive)
Overall, 33% of patients (9325 of 28,628) who were newly
started on an ACEI or ARB went on to initiate another
antihypertensive medication in succession (Table 3). Within
this subgroup, the second drug in 701 patients also inhibited
the renin–angiotensin axis such that these patients took
combination therapy (ACEIþARB). A total of 8624 patients
were initiated on a non-renin–angiotensin-blocking agent in
the setting of continued ACEI (ACEIþ non-ARB, n¼ 6866)
or ARB (ARBþ non-ACEI, n¼ 1758) use. Patients were
followed up for an average of 1.46 years (ACEIþARB users:
1.46 years; ACEIþ non-ARB users: 1.47 years; ARBþ non-
ACEI users: 1.43 years).
Patients initiated on combination ACEI and ARB therapy
were older, were more likely to be black, diabetic, have
had congestive heart failure, have CAD, and to take anti-
platelet drugs, and took more antihypertensive medication
than did patients initiated on an ACEI or ARB with another
class of antihypertensive therapy. No statistically significant
Table 1 | Baseline characteristics of end-stage renal disease
(ESRD) patients initiated on treatment with an angiotensin-
converting enzyme inhibitor (ACEI) or an angiotensin
receptor blocker (ARB)
ACEI ARB P-value
Propensity
score
adjusted
P-valuea
N 22,800 5828
Age (years) 61.0 (0.1) 61.1 (0.1) 0.68 0.90
Vintage (years) 2.7 (0.02) 2.8 (0.04) 0.03 0.82
Gender (% male) 52.4 (0.2) 48.1 (0.2) o0.0001 0.84
Race
Black (%) 38.2 (0.2) 36.4 (0.2) 0.003 0.64
White (%) 53.2 (0.2) 53.8 (0.2)
Other (%) 8.6 (0.1) 9.8 (0.1)
Access
AVF (%) 25.3 (0.2) 24.5 (0.2) 0.53 0.42
Catheter (%) 27.2 (0.2) 27.9 (0.2)
Graft (%) 42.8 (0.2) 42.9 (0.2)
Unknown (%) 4.7 (0.1) 4.7 (0.1)
Blood pressure (mmHg)
Pre-HD SBP 160.5 (0.1) 162.9 (0.2) o0.0001 0.65
Pre-HD DBP 82.4 (0.08) 83.3 (0.1) o0.0001 0.53
Post-HD SBP 148.4 (0.1) 150.1 (0.2) o0.0001 0.63
Post-HD DBP 76.1 (0.08) 76.9 (0.1) o0.0001 0.64
BMI (kg/m2) 27.3 (0.05) 27.9 (0.1) o0.0001 0.54
Laboratory
Hemoglobin (g/dl) 11.4 (0.01) 11.5 (0.02) o0.0001 0.39
Albumin (g/dl) 3.8 (0.003) 3.8 (0.006) o0.0001 0.96
Potassium (mequiv./l) 4.8 (0.005) 4.8 (0.01) 0.02 0.98
Dialysate potassium
(mequiv./l)
2.1 (0.003) 2.1 (0.007) 0.87 0.97
Dialysis adequacy (eKt/V) 1.41 (0.01) 1.40 (0.007) 0.74 0.88
Comorbidity
Charlson’s comorbidity 4.6 (0.01) 4.5 (0.02) o0.0001 0.96
Diabetic (%) 53.2 (0.2) 50.9 (0.2) 0.001 0.67
CAD or past MI (%) 20.0 (0.2) 18.1 (0.2) 0.001 0.90
PVD (%) 18.4 (0.2) 17.4 (0.2) 0.08 0.66
CHF (%) 27.7 (0.3) 25.1 (0.3) o0.0001 0.58
Past stroke (%) 6.2 (0.1) 5.0 (0.2) 0.0002 0.69
Medications
EPO (1000Units per session) 5.7 (0.03) 6.0 (0.08) 0.003 0.82
Vitamin D (% use) 74.6 (0.2) 75.5 (0.2) 0.13 0.59
Antiplatelet (% use) 33.8 (0.2) 32.1 (0.2) 0.01 0.52
Warfarin (% use) 10.1 (0.1) 10.0 (0.1) 0.95 0.93
Statin (% use) 21.2 (0.2) 22.6 (0.2) 0.02 0.71
Antihypertensive drugs
1 drug (%) 36.5 (0.2) 33.7 (0.2) o0.0001 0.96
2 drugs (%) 35.7 (0.2) 34.7 (0.2)
X3 drugs (%) 27.8 (0.2) 31.7 (0.2)
Abbreviations: AVF, arteriovenous fistula; BMI, body mass index; CAD, coronary
artery disease; CHF, congestive heart failure; DBP, diastolic blood pressure; EPO,
erythropoietin; MI, myocardial infarction; post-HD, post-dialysis; pre-HD, pre-dialysis;
PVD, peripheral vascular disease; SBP, systolic blood pressure.
aP-value between the ACEI and ARB groups with propensity score adjustment;
components of the propensity score include age, gender, vintage, race (black, white,
other), cause of ESRD (diabetic, hypertension, glomerulonephritis, other), access
(fistula, graft, catheter, unknown), BMI, blood pressure (pre- and post-dialysis,
systolic, and diastolic), dialysis adequacy (eKt/V), laboratory values (albumin,
calcium, phosphorus, hemoglobin, white blood cell count, creatinine, ferritin,
parathyroid hormone, bicarbonate, transferrin saturation, potassium), dialysate
potassium, residual renal function (yes versus no), entry date, Charlson’s comorbidity
score, diabetic status, other comorbidities (documented myocardial infarction,
CAD, peripheral vascular disease, stroke, transient ischemic attack, malnutrition,
other cardiac disease, atrial fibrillation, menopause, family history of CAD), high-
density lipoprotein-C 435mg/dl, facility standardized mortality ratio, EPO dose,
medication use (vitamin D, digoxin, nitroglycerin, warfarin, statin, antiplatelet agent),
number of antihypertensive drugs prescribed at baseline.
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differences in baseline blood pressure (Table 3) or lowering of
blood pressure over time were evident among the three
treatment groups. Implementation of propensity scores
removed most statistical differences in baseline characteristics
between treatment groups, except for age and statin use;
however, the differences for these parameters were of little
clinical significance. The number of events for mortality and
adverse events within this part of the analysis is listed in
Table 4.
Differences in outcomes were not statistically different
among the groups in the unadjusted model (Table 4 and
Figure 2a). After adjustment for baseline covariates and
weighting for the inverse probability of treatment, combina-
tion ACEI and ARB therapy was statistically significantly
associated with the highest risk of cardiovascular death,
whereas ARBþ non-ACEI anti-hypertensive therapy was
associated with the lowest risk of cardiovascular death among
the three groups (Table 4 and Figure 2b). After stratification
by patient characteristics, significant interaction effects
were noted for gender (P¼ 0.02) and CAD (P¼ 0.03) in
the ACEIþARB versus ACEIþ non-ARB group analysis
(Supplementary Figure S2 online). Interestingly, patients
with CAD or history of myocardial infarction fared better
on the ACEIþARB combination versus the ACEIþ non-
ARB group (HR¼ 1.66; 95% confidence interval 1.02–2.69,
Supplementary Figure S2 online), but not versus the ARBþ
non-ACEI group (HR¼ 1.1, 95% confidence interval
0.63–1.91).
Adverse events
No statistical differences in the risk of hyperkalemia,
post-dialysis orthostatic hypotension, or fall were noted
among any of the groups (Tables 2 and 4).
DISCUSSION
We examined the relationship between the new initiation of
an ACEI or ARB and cardiovascular deaths in422,000 CHD
patients followed for up to 2 years. After adjustment for
risk factors, there was no significant difference in the risk
of cardiovascular, all-cause, or cerebrovascular mortality in
patients initiated on an ARB versus ACEI. In those patients
who required another anti-hypertensive medication in
addition to either an ACEI or an ARB, combination
ACEIþARB treatment was associated with the highest
cardiovascular mortality. On the other hand, ARB alone
with the addition of a non-renin–angiotensin antihyperten-
sive was associated with improved cardiovascular survival.
Both ACEIs and ARBs are effective anti-hypertension
medications that decrease morbidity and mortality through
normalization of high blood pressure.21,22 Although there are
no direct comparisons between the two classes of drugs in
patients with chronic kidney disease, the current body
of evidence, albeit limited, supports cardiovascular benefit
from ARBs, but the effectiveness of ACEIs has yet to be
substantiated.6–14 In particular, (1) fosinopril (ACEI) did not
significantly reduce cardiovascular events in CHD patients in
the randomized trial FOSInopril in DIALysis study (n¼ 397);17
(2) ARBs significantly decreased cardiovascular events and
mortality when compared with untreated patients (n¼ 80) in
a trial by Takahashi et al.;23 and (3) Suzuki et al.24 observed a
significant 49% decrease in fatal and non-fatal cardiovascular
events in a randomized trial of ARB versus no ARB (n¼ 360).
We found that patients on an ARB experienced small,
non-significant survival, and cardiovascular benefits when
compared with an ACEI after adjustment for baseline patient
characteristics.
To further explore the potential clinical impact of blocking
the renin–angiotensin system with drugs with distinct
biological effects, we examined the comparative effectiveness
of ACEIs and ARBs used singly or in combination in ESRD
patients undergoing hemodialysis. Studies of combined ACEI
and ARB use in patients without chronic kidney disease have
provided conflicting data with respect to cardiovascular
benefit and some concern for harm. In Candesartan Heart
Table 2 | Number of events and mortality hazard ratios in end-stage renal disease (ESRD) patients initiated on treatment
with an angiotensin receptor blocker (ARB) compared with those initiated on an angiotensin-converting enzyme
inhibitor (ACEI)
Number of events Hazard ratios (95% CI)
ARB
(N=5828)
ACEI
(N=22,800)
Unadjusted
model (n=28,628)
Adjusted modela
(n=24,452)
Matched modelb
(n=9760)
Risk of cardiovascular death 620 (10.6%) 2856 (12.5%) 0.87 (0.80–0.95) 0.96 (0.89–1.04) 0.90 (0.80–1.01)
Risk of death from any cause 1433 (24.6%) 6386 (28.0%) 0.90 (0.85–0.95) 0.98 (0.93–1.03) 0.95 (0.88–1.03)
Risk of cerebrovascular death 74 (1.3%) 250 (1.1%) 1.19 (0.92–1.54) 1.16 (0.92–1.46) 1.18 (0.81–1.72)
Hyperkalemia 1635 (28.1%) 6876 (30.2%) 0.93 (0.88–0.98) 0.97 (0.92–1.01) 1.01 (0.92–1.11)
Orthostatic blood pressure 4027 (69.1%) 14 681 (64.4%) 1.15 (1.11–1.19) 1.00 (0.97–1.03) 0.97 (0.92–1.03)
Risk of fall 37 (0.6%) 141 (0.6%) 1.05 (0.73–1.91) 1.21 (0.88–1.68) 1.00 (0.56–1.80)
Abbreviations: CI, confidence interval; EPO, erythropoietin.
aModels were adjusted for the following covariates: age, gender, vintage, race (black, white, other), cause of ESRD (diabetic, hypertension, glomerulonephritis, other), access
(fistula, graft, catheter, unknown), body mass index, blood pressure (pre- and post-dialysis, systolic, and diastolic), dialysis adequacy (eKt/V), laboratory values (albumin,
calcium, phosphorus, hemoglobin, white blood cell count, creatinine, ferritin, parathyroid hormone, bicarbonate, transferrin saturation, potassium), dialysate potassium,
residual renal function (yes versus no), entry date, Charlson’s comorbidity score, diabetic status, other comorbidities (documented myocardial infarction, coronary artery
disease, peripheral vascular disease, stroke, transient ischemic attack, malnutrition, other cardiac disease, atrial fibrillation, menopause, family history of coronary artery
disease), high-density lipoprotein-C435mg/dl, facility standardized mortality ratio, EPO dose, medication use (vitamin D, digoxin, nitroglycerin, warfarin, statin, antiplatelet
agent), number of antihypertensive drugs prescribed at baseline.
bPatients on treatment with either ARB or ACEI were 1:1 matched on propensity score.
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Failure-Assessment of moRtality and Morbidity (CHARM)-
added, randomization to candesartan (ARB) was associated
with a reduced risk of cardiovascular death or hospitalization
in patients already taking an ACEI.14 In the Val-HeFT
(Valsartan Heart Failure Trial), randomization to valsartan
improved morbidity in congestive heart failure patients
taking an ACEI or a b-blocker, but worsened morbidity and
mortality in patients previously taking both an ACEI and a
b-blocker.12 In the VALIANT (Valsartan in Acute Myocardial
Infarction Trial) and ONTARGET (ONgoing Telmisartan
Alone and in Combination with Ramipril Global Endpoint
Trial) studies,6,7 combination ACEI and ARB therapy lowered
blood pressure and increased the risk for hypotension without
improving cardiovascular outcomes; furthermore, ONTARGET-
reported combination therapy showed a trend toward an
increased risk of myocardial infarction, cardiovascular death,
revascularization, angina, and all-cause mortality.
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Figure 1 |Cardiovascular survival curves. (a) Crude and
(b) adjusted survival curves in patients in whom angiotensin-
converting enzyme inhibitor (ACEI) or angiotensin receptor
blocker (ARB) therapy was initiated.
Table 3 | Baseline characteristics in ESRD subjects started on
an ACEI or ARB followed by another concomitant
antihypertensive medication
ACEI+other
drug
ARB+other
drug ACEI+ARB P-value
Propensity
score
adjusted
P-valuea
N 6866 1758 701
Age (years) 59.9 (0.1) 60.6 (0.3) 61.7 (0.5) 0.004 0.64
Vintage (years) 3.3 (0.04) 3.3 (0.07) 3.2 (0.1) 0.73 0.95
Gender (%male) 50.9 (0.5) 45.9 (0.5) 46.1 (0.5) 0.0002 0.0003
Race
Black (%) 42.8 (0.5) 39.3 (0.5) 43.5 (0.5) 0.03 0.44
White (%) 49.1 (0.5) 51.1 (0.5) 47.1 (0.5)
Other (%) 8.1 (0.2) 9.6 (0.3) 9.4 (0.3)
Access
AVF (%) 27.4 (0.4) 26.4 (0.4) 29.0 (0.4) 0.64 0.39
Catheter (%) 24.8 (0.4) 25.8 (0.4) 24.3 (0.4)
Graft (%) 44.2 (0.5) 44.0 (0.5) 44.2 (0.5)
Unknown (%) 3.5 (0.1) 3.8 (0.1) 2.6 (0.1)
Blood pressure (mmHg)
Pre-HD SBP 166.3 (0.2) 167.5 (0.4) 166.2 (0.7) 0.04 0.70
Pre-HD DBP 85.6 (0.1) 86.0 (0.2) 85.2 (0.4) 0.32 0.95
Post-HD SBP 154.0 (0.2) 154.6 (0.4) 153.1 (0.7) 0.23 0.83
Post-HD DBP 79.3 (0.1) 79.4 (0.2) 78.5 (0.4) 0.20 0.98
BMI (kg/m2) 27.2 (0.09) 27.7 (0.1) 27.6 (0.2) 0.01 0.45
Laboratory
Hemoglobin (g/dl) 11.4 (0.01) 11.5 (0.03) 11.5 (0.05) 0.15 0.83
Albumin (g/dl) 3.8 (0.005) 3.9 (0.01) 3.8 (0.01) 0.04 0.92
Potassium (mequiv./l) 4.8 (0.009) 4.8 (0.01) 4.8 (0.02) 0.13 0.93
Dialysate potassium
(mequiv./l)
2.1 (0.006) 2.1 (0.01) 2.1 (0.02) 0.09 0.09
Dialysis adequacy (eKt/V) 1.41 (0.005) 1.40 (0.01) 1.41 (0.01) 0.64 0.53
Comorbidity
Charlson’s comorbidity 4.7 (0.02) 4.5 (0.04) 4.7 (0.07)o0.0001 0.34
Diabetic (%) 52.1 (0.5) 48.9 (0.5) 53.8 (0.5) 0.02 0.16
CAD or past MI (%) 20.9 (0.4) 18.9 (0.4) 23.1 (0.4) 0.04 0.18
CHF (%) 29.9 (0.5) 26.3 (0.5) 31.0 (0.5) 0.008 0.20
PVD (%) 19.8 (0.4) 17.0 (0.3) 18.0 (0.3) 0.02 0.40
Past stroke (%) 7.1 (0.2) 6.5 (0.2) 4.9 (0.2) 0.07 0.54
Medications
EPO (1000Units per
session)
6.2 (0.07) 6.5 (0.1) 6.4 (0.2) 0.07 0.97
Vitamin D (% use) 81.4 (0.4) 81.5 (0.4) 82.2 (0.3) 0.87 0.74
Antiplatelet (% use) 35.8 (0.4) 33.3 (0.4) 38.7 (0.5) 0.03 0.92
Warfarin (% use) 9.5 (0.3) 9.8 (0.3) 7.6 (0.2) 0.19 0.28
Statin (% use) 22.2 (0.4) 23.1 (0.4) 25.4 (0.4) 0.14 0.01
Antihypertensive drugs
2 drug (%) 46.4 (0.5) 44.7 (0.5) 34.2 (0.4) o0.0001 0.94
3 drugs (%) 35.4 (0.4) 34.4 (0.4) 37.5 (0.5)
X4 drugs (%) 18.2 (0.4) 20.9 (0.4) 28.2 (0.4)
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin
receptor blocker; AVF, arteriovenous fistula; BMI, body mass index; CAD, coronary
artery disease; CHF, congestive heart failure; DBP, diastolic blood pressure;
EPO, erythropoietin; ESRD, end-stage renal disease; MI, myocardial infarction;
post-HD, post-dialysis; pre-HD, pre-dialysis; PVD, peripheral vascular disease;
SBP, systolic blood pressure.
aP-value between ACEI and ARB group after adjustment for the propensity score.
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We found that among hemodialysis patients initiated
on two antihypertensive medications, combination ACEI
and ARB treatment was associated with the highest risk of
cardiovascular and all-cause mortality. Patients on an ARB
without concomitant ACEI use had the lowest risk of
cardiovascular death. In a subanalysis, among patients with
preexisting CAD, combination ACEIþARB was superior
to ACEIþ non-ARB but comparable to ARBþ non-ACEI.
The mechanism by which ARB alone or ARB-based
combination therapy could lead to reduced cardiovascular
mortality in patients with ESRD compared with ACEI-based
combination therapy has not been well elucidated.
A potential mechanism could be through the differential
effects on oxidative stress and inflammation, which predict
cardiovascular mortality in hemodialysis patients.25,26 During
hemodialysis, contact of blood with the dialyzer and dialysate
activates the kallikrein–kinin system and induces a systemic
inflammatory reaction characterized by complement activa-
tion, leukocyte activation, and the generation of cytokines,
with subsequent oxidative stress.27,28 By decreasing the
formation or action of angiotensin II (Ang II), ACEIs and
ARBs reduce oxidative stress and inflammation.29 However,
although ACEIs prevent the formation of Ang II, they
also potentiate the actions of bradykinin by inhibiting
its degradation and by altering B2 receptor sensitivity.
30
Bradykinin induces fibrinolysis and stimulates inflamma-
tion.31,32 In hemodialysis patients with underlying endothe-
lial dysfunction, chronic inflammation, and increased
oxidative stress burden,33 it is possible that the proinflam-
matory effects of bradykinin partially negate the beneficial
effects of interrupting the renin–angiotensin system and
reducing blood pressure.
Table 4 |Mortality hazard ratios in hypertensive ESRD
subjects initiated on an ACEI or ARB, followed by another
concomitant antihypertensive medication
Number of
Unadjusted
model
(n=9325)
Adjusted
modela
(n=8282)
events HR (95% CI) HR (95% CI)
Risk of cardiovascular death
ACEI+other anti-HTN drug 514 (7.4%) 1.00 (0.75–1.33) 0.87 (0.72–1.06)
ARB+other anti-HTN drug 107 (6.1%) 0.83 (0.60–1.16) 0.69 (0.57–0.84)
ACEI+ARB 53 (7.4%) 1.00 (ref) 1.00 (ref)
Risk of death from any cause
ACEI+other anti-HTN drug 1171 (17.1%) 1.13 (0.92–1.38) 1.05 (0.92–1.19)
ARB+other anti-HTN drug 268 (15.2%) 1.03 (0.83–1.30) 0.93 (0.81–1.07)
ACEI+ARB 105 (15.0%) 1.00 (ref) 1.00 (ref)
Risk of cerebrovascular death
ACEI+other anti-HTN drug 107 (1.6%) 0.84 (0.47–1.49) 0.75 (0.49–1.15)
ARB+other anti-HTN drug 29 (1.7%) 0.92 (0.48–1.78) 0.88 (0.58–1.35)
ACEI+ARB 13 (1.9%) 1.00 (ref) 1.00 (ref)
Risk of hyperkalemiab
ACEI+other anti-HTN drug 2125 (30.9%) 1.11 (0.96–1.28) 0.98 (0.89–1.08)
ARB+other anti-HTN drug 519 (29.5%) 1.07 (0.91–1.26) 1.01 (0.92–1.11)
ACEI+ARB 199 (28.4%) 1.00 (ref) 1.00 (ref)
Risk of orthostatic BP
ACEI+other anti-HTN drug 4911 (71.5%) 0.90 (0.82–0.99) 1.22 (0.91–1.64)
ARB+other anti-HTN drug 1291 (73.4%) 0.97 (0.49–1.22) 1.24 (0.92–1.66)
ACEI+ARB 521 (74.3%) 1.00 (ref) 1.00 (ref)
Risk of fallc
ACEI+other anti-HTN drug 246 (3.6%) 0.92 (0.62–1.36) 0.98 (0.92–1.04)
ARB+other anti-HTN drug 52 (2.9%) 0.77 (0.49–1.22) 0.98 (0.92–1.04)
ACEI+ARB 27 (3.9%) 1.00 (ref) 1.00 (ref)
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin
receptor blocker; CI, confidence interval; ESRD, end-stage renal disease; HR, hazard
ratio; HTN, hypertensive.
aModels are covariate and propensity score adjusted. The scores were weighted
using the inverse probability of treatment.
bDefined as a pre-dialysis serum potassium X6.5mequiv./l.
cDefined as a 420mmHg decrease in standing versus seated systolic pressure
or 410mmHg decrease in standing versus seated diastolic pressure measured
after dialysis.
Crude survival (%)a
b Adjusted survival (%)
1.000
0.975
0.950
0.925
P = 0.21
P = 0.001
ACEI+ARB
ACEI+ARB
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Figure 2 |Cardiovascular survival curves. (a) Crude and
(b) adjusted survival curves in patients in whom treatment
was initiated with an ACEIþ other antihypertensive (antiHTN)
medications (ACEIþ Rx), an angiotensin receptor blocker
(ARB)þ antiHTN (ARBþ Rx), or an ACEIþARB. ACEI, angiotensin-
converting enzyme inhibitor.
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Several limitations warrant mention. As this was an
observational study, there may have been confounding by
indication. Users of ACEIs were more likely to have risk
factors for cardiovascular events. In contrast, blood pressure
was significantly lower in ACEI users than in ARB users.
Although adjustment for propensity score eliminated base-
line differences between treatment groups and the analysis
controlled for gender, it is possible that there may have been
other differences that we did not measure. For example, we
did not have patient medication histories during their pre-
ESRD period and were not able to statistically adjust for such
a factor. Some patients may have been treated in the past with
ACEIs and ARBs, which were discontinued in the late stages
of pre-ESRD to prevent further loss of glomerular filtration
rate and acceleration of hemodialysis onset. In addition, we
could not measure or adjust for the severity of baseline
comorbidities (such as congestive heart failure), and this may
have confounded the outcome. As information regarding
comorbidities was obtained from the attending physician or
transcribed from medical notes and could not be validated
against diagnostics such as an echocardiogram, there could
have been a misclassification bias. Therefore, the results
should be considered as hypothesis generating and should lead
to further randomized clinical trials. Finally, the ascertainment
of cause of death was based on medical records and was
susceptible to potential misclassification bias.
In summary, in a large cohort of ESRD patients under-
going maintenance hemodialysis, when more than one
antihypertensive agent was added, ARB use was associated
with a cardiovascular mortality benefit over ACEI therapy.
Combination ACEI and ARB therapy was associated with the
highest cardiovascular mortality. Randomized, prospective
trials of ACEIs and ARBs in ESRD will provide valuable
insight into the effects of different renin–angiotensin system-
inhibiting agents in patients on dialysis.
METHODS
We executed two separate cohort analyses to examine the
comparative effectiveness of ACEIs and ARBs with regard to
mortality in a population of ESRD patients. In the first stage of
the analysis, hemodialysis patients initiated on an ACEI were
compared with patients started on an ARB. In a separate second
stage of the analysis, stage 1 patients who progressed to combined
ACEI plus ARB (ACEIþARB) therapy were compared with patients
who were treated with renin–angiotensin system monotherapy
(ACEI or ARB) plus a non-renin–angiotensin antihypertensive.
Population and data source
All prevalent CHD patients from 1 January 1997 to 31 December
2003 from a large United States-based dialysis provider who met the
study criteria were enrolled in this retrospective study. Eligible
patients were identified through the querying of the electronic
medical records, which also provided patient-level data on mortality,
prescription medications, laboratory values, and demographic
information for the analysis. During the study periods, patients
receiving dialysis at an FMCNA (Fresenius Medical Care North
America) clinic were asked to bring their prescription medication
bottles to the dialysis clinic for reconciliation by nursing staff on
admission to the clinic, post-hospitalization, or routinely once
per month. Drug name, start date, and discontinuation date were
updated in the electronic medical records at this time. Thus, oral
medication records tracked all active prescriptions and over-the-
counter medications prescribed by any physician from whom the
patient had sought medical care in a wide range of health-care
settings. All medication data were manually reviewed by a physician
(KC) before inclusion in the study analysis. Full description of the
electronic medical records system used for pharmacoepidemiologi-
cal research has been provided in previous publications.34–37
Enrollment criteria
All prevalent hemodialysis patients were enrolled in the analysis at
the time of first prescription of an ACEI or ARB medication (that
is, ‘new user’), which was the study’s interventional variable.
‘New users’ qualified only if the initiation of an ACEI or ARB was
preceded by a 60-day ‘washout period,’ to prevent the inclusion of
subjects in whom the prescription may have resulted from a
carryover of previous ACEI or ARB therapy. During the 60-day
‘washout period,’ subjects were required to (1) have no ACEI or ARB
use and (2) have no change in their other antihypertensive drugs.
After enrollment, subjects were followed for up to 2 years for
mortality outcomes. Patients were censored users if they transferred
out of the provider network, underwent transplantation, or recovered
their renal function, when they could no longer be followed up for
mortality outcomes within the FMCNA system. All analyses were
conducted as intention to treat, such that subjects were analyzed
according to their initial ACEI or ARB assignment, regardless of
subsequent changes to their anti-hypertensive medication regime.
Outcome
The primary outcome of the study was defined as physician-
documented death from coronary heart disease (myocardial
infarction, sudden death, cardiac arrest, ventricular fibrillation),
CAD (revascularization procedure), or vascular disease (disease of
the aorta or peripheral vasculature). Secondary outcomes included
all-cause mortality or death from stroke. Cause of death was
ascertained from the attending nephrologist’s diagnosis.
Statistical analysis
Baseline patient characteristics were ascertained as the most recent
value on patient enrollment in the study. The distribution of
baseline characteristics, by exposure group, was tabulated and
compared using unadjusted and then propensity score-adjusted
analysis of variance (ANOVA and ANCOVA, respectively) for
continuous variables and logistic models for categorical variables.
The propensity for the prescription of ACEI versus ARB was derived
as a function of all baseline covariates (Table 2) using logistic regres-
sion. The scores were incorporated as inverse probability treatment
weights in statistical models to balance for potential confounding
by indication (see Supplementary Appendix 1 online),38,39 as used in
other studies.40–42 We also directly compared the covariates between
the ACEI and the ARB groups within quintiles of the propensity
score (Supplementary Tables S2–S6 online). We recognize there may
have been other differences we did not measure.
Crude survival curves were obtained using the Kaplan–Meier
method. Unadjusted HRs were initially derived using Cox regression
without the inclusion of covariates or propensity score into the
model. Covariate-adjusted survival curves (HR) were generated with
the addition of propensity score weighting with further adjustment
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of 47 baseline patient characteristics (listed in the footnote to
Table 2) when the ratio of events to covariates was o10 (ref. 43).
A group of patients receiving either ACEI or ARB (n¼ 4880 in each
treatment group) were matched on propensity score. HRs were also
calculated for this matched cohort. Subgroup analysis by age, gender,
race, vintage (years of chronic dialysis at study enrollment), diabetic
status, presence of CAD, presence of congestive heart failure, past
history stroke, and number of antihypertensive medications prescribed
at study entry was also performed, as well as testing for effect
modification through the addition of an interaction term
(drug covariate) to the model. Statistical computations were
accomplished with SAS version 9.1 (Cary, NC).
Second analysis: combined ACEI and ARB therapy
A subpopulation of the original study cohort was further studied in
a separate analysis to examine the effectiveness of combined (ACEI
and ARB) versus one of the renin–angiotensin system-blocking
therapies (either ACEI or ARB) one plus other antihypertensive drug.
In particular, subjects who initially qualified for the ACEI versus
ARB analysis outlined above were entered in a separate analysis if
they continued their ACEI or ARB therapy and an additional
antihypertensive medication was subsequently added. Thus, patients
who were prescribed additional antihypertensive medications were
classified according to the combination of their two antihypertensive
medications (three exposure groups):
(1) ACEIþARB: the subject was started on an ACEI while
continuing ARB therapy (or vice versa).
(2) ACEIþ non-ARB: the subject was started on a non-renin–
angiotensin antihypertensive medication while continuing
ACEI therapy.
(3) ARBþ non-ACEI: the subject was started on a non-renin–
angiotensin antihypertensive medication while continuing
ARB therapy.
Examples of a non-renin–angiotensin antihypertensive medication
included a calcium channel blocker, a1-blocker, a2-agonist, b-blocker,
hydralazine, minoxidil, or labetalol. For this analysis, baseline patient
characteristics were ascertained at the initiation of the second
antihypertensive therapy, and subjects were followed for up to 2 years
from the time the additional antihypertensive medication was
subsequently added. Except for the use of multinomial logistic
regression for the propensity score calculation (that is, 42 exposure
groups, see Supplementary Appendix S1 online),44 outcomes, covari-
ates, and statistical methods were otherwise identical to the analyses as
outlined above. Propensity score matching was not performed in the
second analysis because the three-group matching would result in a
significantly reduced sample size. In addition, three-group propensity
score matching has not been validated by the biostatistical literature
and it is not supported by existing statistical software packages.
Adverse events
The relative time to hyperkalemia, in-center fall, and orthostatic
hypotension by drug exposure group were also determined using
covariate- and propensity score-adjusted Cox regression. The scores
were weighted using the inverse probability of treatment. Hyperka-
lemia was defined as a predialysis serum potassium level of
X6.5mmol/l that was not accompanied by hemolysis. Orthostatic
hypotension was defined as a X20mmHg decrease in systolic or
X10mmHg decrease in diastolic blood pressure from the standing
to sitting position after dialysis.
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